Stories about Medizin, Gesundheit

Bertelsmann Stiftung

More than half of all young people in the EU feel lonely

Gütersloh (ots) - Many young adults in the EU share the feeling that they are lonely. Around 57 per cent of young Europeans aged from 18 to 35 feel moderately or strongly lonely, according to a new Bertelsmann Stiftung study entitled “Loneliness of Young People Compared across Europe in 2024.” The data for the EU-wide survey derive from the European opinion research tool eupinions. While loneliness among young people ...

Accord Healthcare

Accord Healthcare is granted marketing authorisation for IMULDOSA®, ustekinumab biosimilar to Stelara®

London (ots/PRNewswire) - - Accord announces that the European Commission (EC has granted marketing authorisation for Imuldosa® (development code: DMB-3115), a biosimilar to Stelara®, indicated for a range of immune medicated inflammatory diseases. - The EC approval follows a positive opinion issued on 19 October ...

Helmholtz Zentrum München

Maria-Elena Torres-Padilla Honored With the Leibniz Prize 2025

Technische Universität München

Complex pancreatic tumor organoids as foundation for new treatment strategies

TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Foundation for new cancer treatment strategies Organoids represent the complex cell landscape of pancreatic cancer - Tumors are composed of cancer cells with a variety of different characteristics. - This contributes significantly to the complexity of pancreatic cancer and makes the disease difficult to treat. - For the ...

Obrist Group

Obrist Group Introduces Alternatives to PFAS and F-Gases

Obrist Group Introduces Alternatives to PFAS and F-Gases Natural Refrigerants Replacing Harmful Forever Chemicals in Cars Lindau/Germany, Lustenau/Austria – December 10 2024 – Per- and polyfluoroalkyl substances (PFAS) are recognized as highly hazardous, and the European Union is preparing to ban these toxic chemicals. The PFAS group also includes F-gases, such as hydrofluorocarbons, which are widely used in cooling ...

Technische Universität München

Removing hazardous PFAS chemicals from drinking water

TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE TUM researchers develop highly effective filter material Removing hazardous PFAS chemicals from drinking water - Metal-organic framework compounds made of zirconium carboxylate as filters - Large-scale use in practice still to come - Contaminated sites caused by PFAS will be with us for several generations ahead The chemicals known as PFAS are considered a severe threat to ...

ARTTIC Innovation GmbH

Reminder: canSERV Call for Service Provision "Training the Next Generation of Cancer Researchers"

STADA Arzneimittel AG

Press Release: STADA welcomes Ingo Schachel as Head of Investor Relations

Strides Pharma International AG

Strides Pharma Consolidates European Business-to-Business Operations in Switzerland

European Alliance Against Depression

First European Patient Congress Depression for those affected by depression and their close relations takes place online on December 7, 2024 / Free online-event offers information and experience-sharing

Frankfurt am Main (ots) - The European Patient Congress Depression, hosted by the European Alliance Against Depression (EAAD), will take place on December 7, 2024. This free online-event is designed to support individuals affected by depression and their relatives, providing a platform for expert guidance, patient ...

Ottobock SE & Co. KGaA

4

IKEA partners with 'SUITX by Ottobock' / 400+ exoskeletons deployed across 14 countries

Helmholtz Zentrum München

Inceptor Regulates Insulin Homeostasis: A New Approach for Diabetes Therapies

Technische Universität München

New method for designing artificial proteins

TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Designing large new proteins with AI New method for designing artificial proteins - Efficient design of new proteins with desired properties - Size of newly designed proteins is approaching that of antibodies - Predicted protein structures successfully validated in experiments Protein design aims to create customized antibodies for therapies, biosensors for diagnostics, or ...

SHL Medical

2

SHL Medical announces plans to establish SHL Advantec

Lamilux Heinrich Strunz GmbH

LAMILUX AntiBac Wins “Best Food Safety Innovation of the Decade” at the Gulfood Manufacturing Awards 2024

ARTTIC Innovation GmbH

Last Call for canSERV Third Open Call Funding

Technische Universität München

Robotic shorts support people when walking

TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE TUM researchers develop shorts with motor power Robotic shorts support people when walking - Same concept as the electric bike, but for walking - Target groups are the elderly as well as people with cardiovascular conditions - Testers used up to 18% less of their own energy to cover a defined distance Researchers at the Technical University of Munich (TUM) have developed ...

Grünenthal Group

Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain

Aachen, Germany/Morristown, N.J. (ots) - - The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures[1], thus affecting more than 3 million people with surgical procedures ...

LAUDA DR. R. WOBSER GMBH & CO. KG

40th work anniversary at the world market leader

Pulsenmore Ltd.

Pulsenmore Expands Partnership with Clalit Health Services to Deliver 25,000 Home Ultrasound Devices for Remote Prenatal Care

Ramat Gan, Israel (ots/PRNewswire) - Pulsenmore (TASE: PULS), a pioneering provider of home-based ultrasound technology, has announced the renewal and expansion of its strategic partnership with Clalit Health Services, Israel's largest HMO. Over the next five years, Pulsenmore will supply 25,000 units of its ...

LAUDA DR. R. WOBSER GMBH & CO. KG

LAUDA honors Rainer Deinert for 45 years of company loyalty

Ottobock SE & Co. KGaA

Ottobock invests in NeuroTech company ONWARD® Medical

Grünenthal Group

First participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist

Aachen, Germany (ots) - Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the ...

ARTTIC Innovation GmbH

Event Announcement: VIROFIGHT Hybrid Symposium